What ' s Going On With BridgeBio Pharma Stock On Monday?

Monday, BridgeBio Pharma Inc BBIO and Bayer AG BAYRY BAYZF announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe. In exchange, BridgeBio will receive up to $310 million, including upfront and near-term milestone payments and…#bayerag #bridgebio #bayer #attrcm #citianalyst #transthyretin #ttr #fda #nda #pdufa
Source: Reuters: Health - Category: Consumer Health News Source Type: news